GSK Australia's Jemperli - a PD-1 immunotherapy - is now the only TGA-indicated and PBS-reimbursed treatment for patients with primary advanced or recurrent mismatch repair deficiency endometrial cancer.
The treatment is in combination with platinum-containing chemotherapy, unless contraindicated or not tolerated, stated GSK.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 May 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 May 24
